News Novo Nordisk returns to ABPI fold after two-year suspension Novo Nordisk has reached the end of its two-year suspension from the ABPI for breaches of its code of practice after making "sustained improvements."
News AZ, Leo, and Daiichi Sankyo rapped for ad transgressions Leo Pharma, AstraZeneca, and Daiichi Sankyo are the latest drugmakers to fall foul of UK guidelines on advertising of medicines.
News Novo Nordisk suspended from ABPI after code breach The two-year ban reflects "serious breaches” of the trade organisation’s code of practice.
News ABPI code updated with first social media guidance Guidance on the way pharma companies communicate about prescription medicines has been updated in the UK to cover use of social media channels for the first time.
Views & Analysis New IFPMA and EFPIA guidance on use of social media by the p... On 28 September 2022, the international and European self-regulatory bodies for the research-based pharmaceutical industry (I
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.